Research Analysts’ Recent Ratings Changes for Varex Imaging (VREX)

Several brokerages have updated their recommendations and price targets on shares of Varex Imaging (NASDAQ: VREX) in the last few weeks:

• 8/17/2026 – Varex Imaging was downgraded by CJS Securities from “outperform” to “market perform”.
• 8/11/2026 – Varex Imaging was upgraded by Weiss Ratings from “sell (d-)” to “sell (d+)”.
• 8/10/2026 – Varex Imaging was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
• 8/10/2026 – Varex Imaging was downgraded by B. Riley Financial, Inc. from “buy” to “hold”.
• 8/10/2026 – Varex Imaging had its “neutral” rating reaffirmed by Sidoti. They now have a $19.00 price target on the stock.
• 7/27/2026 – Varex Imaging was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/4/2026 – Varex Imaging was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/24/2026 – Varex Imaging had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Varex Imaging Corporation is a global provider of X-ray imaging components and solutions for the medical, security and industrial markets. The company designs, develops and manufactures a broad range of products that convert X-ray energy into high-resolution digital images. Its portfolio includes X-ray tubes, flat panel detectors, digital sensors, specialty radiographic tubes and related software, all engineered to meet the demanding requirements of original equipment manufacturers (OEMs) in diagnostic imaging, computed tomography (CT), fluoroscopy, mammography, dental radiography and non-destructive testing applications.

The company’s medical imaging offerings support a wide spectrum of clinical modalities, from portable radiography systems to advanced CT scanners, enhancing image quality and dose efficiency for healthcare providers.